Molecular surveillance for carbapenemase genes in carbapenem-resistant Pseudomonas aeruginosa in Australian patients with cystic fibrosis

Pathology

Volumn 47, Issue 2, 2015, Pages 156-160

  Tai, Anna S ^a,b   Kidd, Timothy J ^a   Whiley, David M ^a   Ramsay, Kay A ^a   Buckley, Cameron ^a   Bell, Scott C ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Carbapenemase; Cystic fibrosis; Integron; Metallo b lactamase (MBL); Pseudomonas aeruginosa; Real time PCR

Indexed keywords

BACTERIAL DNA; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CARBAPENEMASE;

ADULT; ANTIBIOTIC RESISTANCE; AUSTRALIA; CROSS-SECTIONAL STUDY; CYSTIC FIBROSIS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ADULT; AUSTRALIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84922695881     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000216     Document Type: Article

References (35)

1. Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2011; 2: 65.
2. Yong D, Toleman MA, Bell J, et al. Genetic and biochemical characterization an acquired subgroup B3 metallo-beta-lactamase gene, blaAIM-1, and its unique genetic context in Pseudomonas aeruginosa from Australia. Antimicrob Agents Chemother 2012; 56: 6154-9.
3. Carattoli A, Fortini D, Galetti R., et al. Isolation of NDM-1-producing Pseudomonas aeruginosa sequence type ST235 from a stem cell transplant patient in Italy, May 2013. Euro Surveill 2013; 18: 20633.
4. Rieber H, Frontzek A, von Baum H, et al. Emergence of metallo-beta-lactamases GIM-1 and VIM in multidrug-resistant Pseudomonas aeruginosa in North Rhine-Westphalia, Germany. J Antimicrob Chemother 2012; 67: 1043-5.
5. Herbert S, Halvorsen DS, Leong T, et al. Large outbreak of infection and colonization with gram-negative pathogens carrying the metallo-beta-lactamase gene blaIMP-4 at a 320-bed tertiary hospital in Australia. Infect Control Hosp Epidemiol 2007; 28: 98-101.
6. Zavascki AP, Gaspareto PB, Martins A.F., et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing SPM-1 metallo-{beta}-lacta-mase in a teaching hospital in southern Brazil. J Antimicrob Chemother 2005; 56: 1148-51.
7. Poirel L, Nordmann P, Lagrutta E., et al. Emergence of KPC-producing Pseudomonas aeruginosa in the United States. Antimicrob Agents Chemother 2010; 54: 3072.
8. Laupland KB, Parkins MD, Church D.L., et al. Population-based epidemio-logical study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains. J Infect Dis 2005; 192: 1606-12.
9. Peleg AY, Franklin C, Bell J.M., et al. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005; 41: 1549-56.
10. Walsh TR, Toleman MA, Poirel L, et al. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306-25.
11. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011; 35: 736-55.
12. Kim MJ, Bae IK, Jeong S.H., et al. Dissemination of metallo-beta-lacta-mase-producing Pseudomonas aeruginosa of sequence type 235 in Asian countries. J Antimicrob Chemother 2013; 68: 2820-4.
13. Edelstein MV, Skleenova EN, Shevchenko O.V., et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis 2013; 13: 867-76.
14. Emerson J, McNamara S, Buccat A.M., et al. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010; 45: 363-70.
15. Valenza G, Tappe D, Turnwald D., et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cystic Fibrosis 2008; 7: 123-7.
16. Henrichfreise B, Wiegand I, Pfister W., et al. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother 2007; 51: 4062-70.
17. Pollini S, Fiscarelli E, Mugnaioli C., et al. Pseudomonas aeruginosa infection in cystic fibrosis caused by an epidemic metallo-beta-lacta-mase-producing clone with a heterogeneous carbapenem resistance phenotype. Clin Microbiol Infect 2011; 17: 1272-5.
18. Perez LR, Antunes AL, Freitas A.L., et al. When the resistance gets clingy: Pseudomonas aeruginosa harboring metallo-beta-lactamase gene shows high ability to produce biofilm. Eur J Clin Microbiol Infect Dis 2012; 31: 711-4.
19. Cardoso O, Alves AF, Leitao R. Metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa isolates from a cystic fibrosis patient. Int J Antimicrob Agents 2008; 31: 375-9.
20. Leung GH, Gray TJ, Cheong E.Y., et al. Persistence of related bla-IMP-4 metallo-beta-lactamase producing Enterobacteriaceae from clinical and environmental specimens within a burns unit in Australia - a six-year retrospective study. Antimicrob Resist Infect Control 2013; 2: 35.
21. Kidd TJ, Ramsay KA, Hu H, et al. Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres. Eur Respir J 2013; 41: 1091-100.
22. Armstrong DS, Nixon GM, Carzino R, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002; 166: 983-7.
23. O'Carroll MR, Syrmis MW, Wainwright C.E., et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J 2004; 24: 101-6.
24. Syrmis M, Bell S, Bye P., et al. High prevalence of a class 1 integron-associated aadB gene cassette in Pseudomonas aeruginosa isolates from an Australian cystic fibrosis patient population. Pathology 2008; 40: 524-5.
25. CLSI. Performance Standards for Antimicrobial Susceptibiltiy Testing; 17th Informational Supplement. CLSI document M100-S17. Wayne PA: Clinical and Laboratory Standards Institute; 2007.
26. Whiley DM, Faux CE, Bialasiewicz S, et al. A simple approach for preparing real-time PCR positive reaction controls for rare or emerging viruses. J Clin Virol 2010; 48: 193-7.
27. Anuj SN, Whiley DM, Kidd T.J., et al. Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time and high-resolution melting curve analysis. Clin Microbiol Infect 2011; 17: 1403-8.
28. Oliver A, Canton R, Campo P., et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251-4.
29. Cornaglia G, Akova M, Amicosante G., et al. Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents 2007; 29: 380-8.
30. Juan C, Gutierrez O, Renom F., et al. Chronic respiratory infectionsbymucoid carbapenemase-producing Pseudomonas aeruginosa strains, a new potential public health problem. Antimicrob Agents Chemother 2008; 52: 2285-6.
31. Knibbs LD, Johnson GR, Kidd T.J., et al. Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis. Thorax 2014; 69: 740-5.
32. Samuelsen O, Buaro L, Giske C.G., et al. Evaluation of phenotypic tests for the detection of metallo-beta-lactamase-producing Pseudomonas aerugi-nosa in a low country. J Antimicrob Chemother 2008; 61: 827-30.
33. Berges L, Rodriguez-Villalobos H, Deplano A., et al. Prospective evaluation of imipenem/EDTA combined disc and Etest for detection of metallo-beta-lactamase-producing Pseudomonas aeruginosa. J Antimicrob Chemother 2007; 59: 812-3.
34. Dortet L, Poirel L, Nordmann P. Rapid detection of carbapenemase-producing Pseudomonas spp. J Clin Microbiol 2012; 50: 3773-6.
35. Dortet L, Poirel L, Nordmann P. Further proofs of concept for the Carba NP test. Antimicrob Agents Chemother 2014; 58: 1269.